EWING, NJ--(Marketwire - October 30, 2008) -DOR BioPharma, Inc. (OTCBB: DORB) (DOR or the Company), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has expanded its collaboration with BurnsAdler Pharmaceuticals, Inc. (BurnsAdler), as DOR's distributor of orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in Canada via the Special Access Programme (SAP). BurnsAdler is a specialty pharmaceutical company based in North Carolina that is also collaborating with DOR in Latin America.
